Pfiz­er says its JAK drug topped Dupix­ent in a head-to-head eczema test — but you'll have to wait on the da­ta

Just a few hours af­ter Sanofi and Re­gen­eron un­veiled a new slate of da­ta for Dupix­ent in chil­dren with eczema, Pfiz­er re­leased its own re­sults for a JAK chal­lenger. And they come from the first such tri­al show­ing a di­rect head-to-head com­par­i­son be­tween the two.

The New York-based drug gi­ant un­corked topline da­ta from a Phase III study pit­ting its abroc­i­tinib against Dupix­ent, say­ing the ex­per­i­men­tal drug notched su­pe­ri­or­i­ty over the block­buster in mod­er­ate to se­vere atopic der­mati­tis. Abroc­i­tinib met both pri­ma­ry end­points, Pfiz­er said, with a high­er pro­por­tion of pa­tients achiev­ing at least a four-point im­prove­ment over base­line in an itch­i­ness scale and at least 90% im­prove­ment on an eczema in­dex.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.